Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. Researchers discovered that for people who carry a specific genetic variation – the K-variant of butyrylcholinesterase, or BChE-K – donezpezil could accelerate cognitive decline.
from Top Health News – ScienceDaily http://ift.tt/2mwPO1w
from Tumblr http://ift.tt/2lRi4ii
No comments:
Post a Comment